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column-passed fractions at day 21. In summary our data show
that by increasing the starting purity of CD4Foxp3CD27
cells a greater expansion of the Treg population can be
achieved, making it more feasible to obtain clinically useful
doses of Treg for immunotherapy protocols to prevent or treat
GVHD. Rapamycin at doses of 5-10 ng/mL inhibits the expan-
sion of cells without the phenotype and function of Tregs, but
higher doses (50-200 ng/mL) are toxic to Tregs.
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Despite advances in pre-transplant immune suppression and do-
nor HLA typing methods acute graft versus host disease (aGvHD)
remains a signiﬁcant problem following allogeneic HSCT. Steroid
therapy is the treatment of choice in severe aGvHD. Steroid
non-responsive aGvHD is associated with increased morbidity and
more importantly death due to organ damage and/or infection
related to the use of continuing immune suppression. Second line
treatments continue to be evaluated. Whatever their initial effects,
presently they have had little impact on overall survival.
Mesenchymal stem cells (MSCs) are poor antigen presenting
cells, not expressing MHC class II or co-stimulatory molecules.
They down regulate allo-reactive T cell responses when added to
mixed lymphocyte cultures. MSCs alter cytokine excretion proﬁles
of dendritic cells, naı¨ve and effector T cells, and NK cells inducing
a more tolerant phenotype.
MSCs have been used successfully in a child with resistant
aGvHD (le Blanc. Lancet 2004).
We conducted an ethically committee approved prospective
phase I/II study of co-infusion of expanded MSCs for treatment of
children with steroid refractory, grade II-IV aGVHD.
MSCs, isolated from parental donor marrow were expanded
under GMP conditions. MSCs either as haploidentical or 3rd party.
Patient characteristics receiving MSCs for steroid refractory GvHD.
LUMC 2005-2006
UPN 1 UPN 2 UPN 3 UPN 4
Male Male Male Female
MDS RC Omens Fanconi
anemia
JMML
12y, 3mo 1 yr, 4mo 6yr, 10mo 1yr, 7mo
Sibling ID ORD ID x 2 Matched UD
BMT
Matched Cord
Blood
GvHD 4
(Skin/GI/
Liver)
4 GI
acute/chronic
plus
CMV/graft
failure
4 (skin/GI/
Liver)
4 GI plus AdV
Steroid/CSA/
Tacrolimus/
MMF
Steroid/
Tacrolimus/
MMF
Steroid/CSA/
Anti TNF	/
anti CD25
Steroid/
Tacrolimus/
MMF
MSC1 3rd
party
MSC2 haplo MSC1 3rd
party
MSC2 3rd party
1.1  106/kg 1.8  106/kg 2.3  106/kg 1.76  106/kg
Male 33 years Female 25 years Male 33 years Female 25 years
2 infusions 2 infusions 2 infusions 2 infusions
430 CR No response 430 CR 430 CR
Died
Klebsilella
sepsis
Died
CMV/GvHD
Alive Limited
cGvHD
skin
Alive small
bowel fibrosis
UPN 5 UPN 6 UPN 7 UPN 8
Male Female Male Female
Kostmaan
syndrome
EBV induced
HLH
MDS RC MDS RC
monosomy 7
3yr, 10mo 6yr, 4mo 13yr, 2 mo 4yr, 2mo
Matched UD
BMT
Cord Plus Haplo
and MM UD
BMT
MUD x 3,
DLI’s
MM Cord blood
4GI acute/
chronic
4 Liver 4 (Skin/GI/
Liver)
4 (Skin/GI/Liver)
AdV
Steroid/CSA/
Anti TNF	/
anti CD25
Steroid/CSA/
Tacrolimus
Steroid/MMF Steroid/CSA/
Tacrolimus
MSC3 3rd
party
MSC2 3rd party MSC1 3rd
party
MSC4 3rd party
1.7 106/kg 2.0 106/kg 1.2  106/kg 2.2  106/kg
Female 35
years
Female 25 years Male 33 years Male 36 years
2 infusions 1 infusion 2 infusions 2 infusions
PR; relapsed
GvHD
Not evaluated 430 CR 430 CR
Died
infection/
GvHD
Died EBV
reactivation
Alive liver
dysfunction
Alive
UPN - Unique patient number; CR - complete response: PR -
partial response; AdV - adenovirus; CMV - cytomegalovirus;
EBV - Epstein Barr virus; HLH - hemaphagocytic lymphohis-
tiocytosis; MDS RC - myelodysplastic syndrome and refractory
cytopenia; JMML - Juvenile myelomonocytic leukemia; CSA -
cyclosporine
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BLOCKING LFA-1 ACTIVATION WITH LOVASTATIN PREVENTS GRAFT-
VERSUS-HOST DISEASE IN MOUSE BONE MARROW TRANSPLANTATION
Wang, Y.1, Li, D.1, Jones, D.1, Bassett, R.1, Sale, G.E.2, Khalili, J.1,
Komanduri, K.V.1, Couriel, D.P.1, Champlin, R.E.1, Molldrem, J.J.1,
Ma, Q.1 1University of Texas M.D. Anderson Cancer Center, Houston,
TX; 2Fred Hutchinson Cancer Research Center, Seattle, WA.
Leukocyte function associated antigen-1 (LFA-1) regulates T cell
adhesion and activation. LFA-1 is constitutively expressed on cell
surface in an inactive state. The control of LFA-1 activation is
critical in inﬂammatory and immune responses. We demonstrated
previously that the I-domain, the ligand binding site of LFA-1,
changes from the low-afﬁnity state to high-afﬁnity state upon
activation. Therapeutic antagonist, such as lovastatin, stabilizes the
I-domain in the low-afﬁnity state and inhibits the LFA-1 activa-
tion. Here, we report that lovastatin can block mouse T cell
adhesion and proliferation in vitro. First, we demonstrated that
lovastatin treatment reduced the mortality and morbidity in the
mouse GVHD model. Lovastatin treatment signiﬁcantly decreased
GVHD mortality with 80% mice survived over 28 days, whereas
more than 70% of the control mice died within the ﬁrst 10 days,
and the p values was 0.045. There were signiﬁcantly reduced tissue
damages in the skin, intestine and liver of lovastatin-treated mice.
Second, we found lovastatin treatment reduced donor T cell hom-
ing to lymph nodes. There was a 65% reduction of CD4 T cells
homing to lymph nodes in lovastatin treatment group compared to
control. The reduction of CD8 T cells was greater with about
76% less cells homing to lymph nodes in the lovastatin treatment
group. Third, we found lovastatin treatment reduced donor-de-
rived T cell proliferation in vivo. There were 37% CD4 and 31%
CD8 T cells remained undivided in the lymph nodes of the
control mice at day 4 post-transplant. The lovastatin-treated mice
had reduced proliferation kinetics of both CD4 and CD8 T
cells with about 55% and 42% remained undivided. In the control
lymph nodes, there were 42% CD4 and 59% CD8 T cells
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